Yang Z - Search Results

1

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.

Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z, Han JQ. Zhang Q, et al. Among authors: yang z. Lung Cancer. 2014 Sep;85(3):339-45. doi: 10.1016/j.lungcan.2014.06.011. Epub 2014 Jul 8. Lung Cancer. 2014. PMID: 25043903 Review.

2

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

Wang S, Yang Z, Wang Z. Wang S, et al. Among authors: yang z. Oncotarget. 2015 Jul 20;6(20):18206-23. doi: 10.18632/oncotarget.4524. Oncotarget. 2015. PMID: 26156021 Free PMC article. Review.

3

Clinical observation of gene expression-guided chemoradiation therapy for nonsurgical esophageal squamous cell carcinoma patients: a retrospective analysis of 36 cases.

Yang Z, Dai H, Lv D, Feng AL, Shu W, Han J. Yang Z, et al. Onco Targets Ther. 2016 Jul 25;9:4561-8. doi: 10.2147/OTT.S105221. eCollection 2016. Onco Targets Ther. 2016. PMID: 27524911 Free PMC article.

4

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, Bao H, Tong X, Wang X, Shao YW, Liu Y, Wang Y, Zhou C. Yang Z, et al. Among authors: yang n. Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5. Clin Cancer Res. 2018. PMID: 29506987

5

Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.

Yang Z, Yang J, Chen Y, Shao YW, Wang X. Yang Z, et al. Among authors: yang j. Target Oncol. 2019 Aug;14(4):369-374. doi: 10.1007/s11523-019-00652-6. Target Oncol. 2019. PMID: 31301016

6

Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.

Wang Y, Han X, Wang X, Sheng W, Chen Z, Shu W, Han J, Zhao S, Dai Y, Wang K, Shi W, Yang Z. Wang Y, et al. Among authors: yang z. Jpn J Clin Oncol. 2019 Dec 27;49(12):1143-1150. doi: 10.1093/jjco/hyz131. Jpn J Clin Oncol. 2019. PMID: 31612912

7

YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.

Dai H, Shao YW, Tong X, Wu X, Pang J, Feng A, Yang Z. Dai H, et al. Among authors: yang z. Cancer Med. 2020 Mar;9(5):1628-1637. doi: 10.1002/cam4.2761. Epub 2019 Dec 18. Cancer Med. 2020. PMID: 31851786 Free PMC article.

8

Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.

Li Q, Jiang M, Han X, Yang Z, Shu W, Ding X. Li Q, et al. Among authors: yang z. J Cancer Res Ther. 2020;16(2):222-229. doi: 10.4103/jcrt.JCRT_710_19. J Cancer Res Ther. 2020. PMID: 32474505 Free article.

9

Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.

Wen Q, Yang Z, Zhu J, Qiu Q, Dai H, Feng A, Xing L. Wen Q, et al. Among authors: yang z. Onco Targets Ther. 2020 Nov 20;13:12003-12013. doi: 10.2147/OTT.S261068. eCollection 2020. Onco Targets Ther. 2020. PMID: 33244242 Free PMC article.

10

Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.

Wen Q, Yang Z, Dai H, Feng A, Li Q. Wen Q, et al. Among authors: yang z. Front Oncol. 2021 Aug 6;11:620246. doi: 10.3389/fonc.2021.620246. eCollection 2021. Front Oncol. 2021. PMID: 34422625 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45,552 results

Search Page